CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $255,455 | -25.4% | 5,628 | -7.7% | 0.00% | 0.0% |
| Q2 2023 | $342,286 | +26.0% | 6,097 | +1.5% | 0.00% | 0.0% |
| Q1 2023 | $271,606 | +6.4% | 6,005 | -4.4% | 0.00% | +50.0% |
| Q4 2022 | $255,323 | -99.9% | 6,281 | -53.4% | 0.00% | -60.0% |
| Q3 2022 | $440,440,000 | +106030.1% | 13,476 | +97.1% | 0.01% | +25.0% |
| Q2 2022 | $415,000 | +22.1% | 6,837 | +26.4% | 0.00% | 0.0% |
| Q1 2022 | $340,000 | +4.3% | 5,410 | +25.6% | 0.00% | +33.3% |
| Q4 2021 | $326,000 | -76.6% | 4,308 | -65.5% | 0.00% | -78.6% |
| Q3 2021 | $1,396,000 | -29.3% | 12,472 | +2.2% | 0.01% | -36.4% |
| Q2 2021 | $1,975,000 | +170.9% | 12,200 | +104.0% | 0.02% | +144.4% |
| Q1 2021 | $729,000 | -58.0% | 5,981 | -44.3% | 0.01% | -55.0% |
| Q4 2020 | $1,735,000 | – | 10,737 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |